JP2017535284A - 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 - Google Patents

免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 Download PDF

Info

Publication number
JP2017535284A
JP2017535284A JP2017543315A JP2017543315A JP2017535284A JP 2017535284 A JP2017535284 A JP 2017535284A JP 2017543315 A JP2017543315 A JP 2017543315A JP 2017543315 A JP2017543315 A JP 2017543315A JP 2017535284 A JP2017535284 A JP 2017535284A
Authority
JP
Japan
Prior art keywords
cells
car
cell
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017543315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535284A5 (enExample
Inventor
ローレンス ジェイ．エヌ． クーパー，
ローレンス ジェイ．エヌ． クーパー，
ハルジート シング，
ハルジート シング，
ヘレン ハルズ，
ヘレン ハルズ，
サイモン オリバレス，
サイモン オリバレス，
ビプレンデュ ジェナ，
ビプレンデュ ジェナ，
クリーナ パテル，
クリーナ パテル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2017535284A publication Critical patent/JP2017535284A/ja
Publication of JP2017535284A5 publication Critical patent/JP2017535284A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017543315A 2014-11-05 2015-11-05 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 Withdrawn JP2017535284A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462075667P 2014-11-05 2014-11-05
US201462075561P 2014-11-05 2014-11-05
US201462075642P 2014-11-05 2014-11-05
US62/075,561 2014-11-05
US62/075,667 2014-11-05
US62/075,642 2014-11-05
US201562169979P 2015-06-02 2015-06-02
US62/169,979 2015-06-02
PCT/US2015/059293 WO2016073755A2 (en) 2014-11-05 2015-11-05 Gene modified immune effector cells and engineered cells for expansion of immune effector cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019203260A Division JP2020022504A (ja) 2014-11-05 2019-11-08 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞

Publications (2)

Publication Number Publication Date
JP2017535284A true JP2017535284A (ja) 2017-11-30
JP2017535284A5 JP2017535284A5 (enExample) 2018-12-13

Family

ID=54548288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017543315A Withdrawn JP2017535284A (ja) 2014-11-05 2015-11-05 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
JP2019203260A Pending JP2020022504A (ja) 2014-11-05 2019-11-08 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019203260A Pending JP2020022504A (ja) 2014-11-05 2019-11-08 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞

Country Status (9)

Country Link
US (2) US20170333480A1 (enExample)
EP (2) EP3215535A2 (enExample)
JP (2) JP2017535284A (enExample)
KR (1) KR20170075785A (enExample)
CN (1) CN107207615A (enExample)
AU (2) AU2015343013B2 (enExample)
CA (1) CA2964785A1 (enExample)
HK (1) HK1243441A1 (enExample)
WO (1) WO2016073755A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013315A1 (ja) * 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
JPWO2020004622A1 (ja) * 2018-06-29 2020-07-16 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
JPWO2021020526A1 (enExample) * 2019-07-31 2021-02-04
WO2021100585A1 (ja) * 2019-11-20 2021-05-27 国立大学法人東海国立大学機構 キメラ抗原受容体遺伝子改変リンパ球の調製方法
JPWO2020085480A1 (ja) * 2018-10-26 2021-09-16 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
JP2021528048A (ja) * 2019-03-05 2021-10-21 ンカルタ・インコーポレイテッドＮｋａｒｔａ， Ｉｎｃ． Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
WO2024058234A1 (ja) * 2022-09-13 2024-03-21 株式会社サイト－ファクト 移植用ｔ細胞およびその製造方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
AU2014265487B2 (en) 2013-05-14 2020-10-22 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
ES2764471T3 (es) 2014-02-14 2020-06-03 Univ Texas Receptores de antígeno quimérico y procedimientos de fabricación
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
EP3240805B1 (en) 2014-12-15 2024-11-27 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA2976126A1 (en) 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
RU2020127887A (ru) 2015-03-11 2020-10-02 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Полипептиды транспозазы и их применение
JP7020687B2 (ja) 2015-09-15 2022-02-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CN110191898B (zh) 2016-06-08 2024-05-10 英特瑞克斯顿股份有限公司 Cd33特异性嵌合抗原受体
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
US20200283534A1 (en) * 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
EP3506943B1 (en) 2016-09-02 2025-01-29 The Regents of The University of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
CN110023497B (zh) 2016-11-07 2021-07-13 杰诺维有限公司 用于t细胞受体合成和向tcr呈递细胞进行稳定的基因组整合的两部分装置
EP4365296A3 (en) * 2016-11-07 2024-07-24 Genovie AB An engineered two-part cellular device for discovery and characterisation of t-cell receptor interaction with cognate antigen
EP4019625B1 (en) * 2016-11-07 2025-04-02 Genovie AB An engineered multi-component system used for selecting t-cell receptors, t-cells and engineered antigen presenting cells.
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
WO2018132494A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
CN108424458A (zh) * 2017-02-13 2018-08-21 上海恒润达生生物科技有限公司 靶向ny-eso-1的嵌合抗原受体及其用途
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
EP3612568B8 (en) * 2017-04-18 2021-12-08 Autolus Limited Cell
AU2018281316B2 (en) 2017-06-07 2024-05-30 Precigen, Inc. Expression of novel cell tags
EP3658163A4 (en) * 2017-07-25 2021-08-04 Board Of Regents, The University Of Texas System NOVEL CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CA3080274A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
US11390655B2 (en) * 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN108103106A (zh) * 2018-01-09 2018-06-01 河南省华隆生物技术有限公司 一种pFTM3GW重组载体及其制备方法和应用
AU2019209432B2 (en) 2018-01-22 2026-01-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN110093351B (zh) * 2018-01-29 2023-06-23 华南生物医药研究院 可分离的核酸、多肽、重组载体、重组细胞及应用
CN111801348A (zh) * 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
KR102226917B1 (ko) * 2018-03-23 2021-03-11 주식회사 에스엘바이젠 신규 유전자 변형 자연살해 세포주 및 그의 용도
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112566643A (zh) * 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
WO2020049496A1 (en) * 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
EP3920941A4 (en) * 2019-02-08 2023-01-18 Dna Twopointo Inc. Transposon-based modifications of immune cells
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
JP7748874B2 (ja) * 2019-03-04 2025-10-03 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体及びその使用方法
CN113710688A (zh) * 2019-03-26 2021-11-26 加利福尼亚大学董事会 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t)
CN110592014A (zh) * 2019-08-14 2019-12-20 广东美赛尔细胞生物科技有限公司 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
GB201918908D0 (en) * 2019-12-19 2020-02-05 Autolus Ltd Cell
CN111264469B (zh) * 2020-02-27 2022-03-25 西安交通大学医学院第一附属医院 一种基因免疫诱导的甲状腺相关性眼病动物模型的构建方法及雷帕霉素类药物的应用
JP2023521037A (ja) * 2020-04-03 2023-05-23 セルビー インコーポレイテッド 養子細胞移植の強化
AU2021320556A1 (en) 2020-08-07 2023-03-09 Neogene Therapeutics B.V. Methods to enrich genetically engineered T cells
WO2022159460A1 (en) * 2021-01-20 2022-07-28 Neogene Therapeutics B.V. Engineered antigen presenting cells
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
JP2009502185A (ja) * 2005-08-05 2009-01-29 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法、抗原特異的ｔ細胞、核酸、ベクター、ｐｂｍｃ、及び製薬組成物
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2014144622A2 (en) * 2013-03-15 2014-09-18 Stephen Forman Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE69435010T2 (de) * 1993-04-20 2008-04-30 Hipler Partners Llp Verfahren und stoffe für die behandlung von individuen, die infiziert sind mit intrazellulär infektiösen agentien
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
DK0969865T3 (da) 1996-05-23 2007-03-19 Scripps Research Inst Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US7993638B2 (en) 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
US8124408B2 (en) 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112014008849A2 (pt) * 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
ES2764471T3 (es) 2014-02-14 2020-06-03 Univ Texas Receptores de antígeno quimérico y procedimientos de fabricación

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
JP2009502185A (ja) * 2005-08-05 2009-01-29 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法、抗原特異的ｔ細胞、核酸、ベクター、ｐｂｍｃ、及び製薬組成物
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2014144622A2 (en) * 2013-03-15 2014-09-18 Stephen Forman Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL RES, EPUB 2014 SEP 11, VOL.3, NO.2, P.125-135, JPN6019032977, ISSN: 0004102771 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020004622A1 (ja) * 2018-06-29 2020-07-16 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
JP2020150950A (ja) * 2018-06-29 2020-09-24 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
JP7479635B2 (ja) 2018-07-13 2024-05-09 国立大学法人京都大学 γδＴ細胞の製造方法
US12391739B2 (en) 2018-07-13 2025-08-19 Kyoto University Method for producing gamma delta T cells
JP2024096899A (ja) * 2018-07-13 2024-07-17 国立大学法人京都大学 γδＴ細胞の製造方法
JPWO2020013315A1 (ja) * 2018-07-13 2021-08-02 国立大学法人京都大学 γδＴ細胞の製造方法
WO2020013315A1 (ja) * 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
JP7632868B2 (ja) 2018-10-26 2025-02-19 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
JPWO2020085480A1 (ja) * 2018-10-26 2021-09-16 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
JP7487112B2 (ja) 2019-03-05 2024-05-20 ンカルタ・インコーポレイテッド Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
JP2021528048A (ja) * 2019-03-05 2021-10-21 ンカルタ・インコーポレイテッドＮｋａｒｔａ， Ｉｎｃ． Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
JP7576547B2 (ja) 2019-07-31 2024-10-31 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
WO2021020526A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
JPWO2021020526A1 (enExample) * 2019-07-31 2021-02-04
JPWO2021100585A1 (enExample) * 2019-11-20 2021-05-27
WO2021100585A1 (ja) * 2019-11-20 2021-05-27 国立大学法人東海国立大学機構 キメラ抗原受容体遺伝子改変リンパ球の調製方法
WO2024058234A1 (ja) * 2022-09-13 2024-03-21 株式会社サイト－ファクト 移植用ｔ細胞およびその製造方法

Also Published As

Publication number Publication date
EP3536707A1 (en) 2019-09-11
US20170333480A1 (en) 2017-11-23
KR20170075785A (ko) 2017-07-03
HK1243441A1 (zh) 2018-07-13
JP2020022504A (ja) 2020-02-13
EP3215535A2 (en) 2017-09-13
CN107207615A (zh) 2017-09-26
AU2015343013A1 (en) 2017-05-11
WO2016073755A3 (en) 2016-06-30
AU2015343013B2 (en) 2020-07-16
US20220072041A1 (en) 2022-03-10
AU2020250247A1 (en) 2020-11-05
WO2016073755A2 (en) 2016-05-12
WO2016073755A9 (en) 2017-07-27
CA2964785A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
US20220072041A1 (en) Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US20200247867A1 (en) Chimeric antigen receptors (car) to selectively target protein complexes
US11344577B2 (en) Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP3105335B1 (en) Chimeric antigen receptors and methods of making
JP2021090444A (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
US20240398950A1 (en) Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells
WO2023020558A1 (en) Modified immune cells expressing tlr receptors
JP2022522027A (ja) 抗原特異的免疫細胞におけるｃｄ１６０機能をモジュレートする方法およびその使用
HK40105048A (zh) 表达tlr受体的经修饰的免疫细胞
HK40115153A (zh) 通过促进优越的适应性免疫细胞群体增强过继细胞转移
HK1243442B (en) Chimeric antigen receptors (car) to selectively target protein complexes
HK1232561B (en) Chimeric antigen receptors and methods of making
HK1232561A1 (en) Chimeric antigen receptors and methods of making

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190828

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20191128